TY - JOUR
T1 - Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals
AU - Valmori, Danila
AU - Souleimanian, Naira E.
AU - Hesdorffer, Charles S.
AU - Old, Lloyd J.
AU - Ayyoub, Maha
N1 - Funding Information:
We would like to thank Dr. E. Hoffmann and Dr. J. Skipper (Ludwig Institute for Cancer Research) for providing the NY-ESO-1 peptides. D. Valmori and M. Ayyoub are supported by the Ludwig Institute for Cancer Research and by the Cancer Research Institute.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/11
Y1 - 2005/11
N2 - The germ cell antigen NY-ESO-1 is characterized by its frequent expression in patients bearing cancers of various histological types, that positively correlates with stage of disease, together with its frequent spontaneous immunogenicity in patients with advanced cancer. Because of these features, NY-ESO-1 is presently viewed as a prototype antigen for the development of cancer vaccines aimed at preventing disease progression. To gain a global view of the CD4+ T cell repertoire available for NY-ESO-1 in individuals of different genetic background, in this study, we have addressed the presence, frequency, and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences among circulating lymphocytes from healthy donors. NY-ESO-1 specific CD4+ T cells were present among circulating lymphocytes at a frequency between 0.5 and 5 precursors per million CD4 + T cells. In the majority of the cases, the reactivity of NY-ESO-1 specific CD4+ T cells was directed towards immunodominant regions located in the carboxyl-terminal half of the protein. Interestingly, immunodominant regions were confined to parts of the NY-ESO-1 protein containing hotspot sequences with predicted high binding for multiple frequently expressed MHC class II molecules. In contrast, no reactivity was found against the amino-terminal part of the protein, which was concomitant with the paucity, in this region, of sequences with predicted high binding to MHC class II molecules.
AB - The germ cell antigen NY-ESO-1 is characterized by its frequent expression in patients bearing cancers of various histological types, that positively correlates with stage of disease, together with its frequent spontaneous immunogenicity in patients with advanced cancer. Because of these features, NY-ESO-1 is presently viewed as a prototype antigen for the development of cancer vaccines aimed at preventing disease progression. To gain a global view of the CD4+ T cell repertoire available for NY-ESO-1 in individuals of different genetic background, in this study, we have addressed the presence, frequency, and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences among circulating lymphocytes from healthy donors. NY-ESO-1 specific CD4+ T cells were present among circulating lymphocytes at a frequency between 0.5 and 5 precursors per million CD4 + T cells. In the majority of the cases, the reactivity of NY-ESO-1 specific CD4+ T cells was directed towards immunodominant regions located in the carboxyl-terminal half of the protein. Interestingly, immunodominant regions were confined to parts of the NY-ESO-1 protein containing hotspot sequences with predicted high binding for multiple frequently expressed MHC class II molecules. In contrast, no reactivity was found against the amino-terminal part of the protein, which was concomitant with the paucity, in this region, of sequences with predicted high binding to MHC class II molecules.
KW - CD4 T cells
KW - Human
KW - T cell epitopes
KW - Tumor immunity
UR - http://www.scopus.com/inward/record.url?scp=26044479667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26044479667&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2005.07.004
DO - 10.1016/j.clim.2005.07.004
M3 - Article
C2 - 16103015
AN - SCOPUS:26044479667
SN - 1521-6616
VL - 117
SP - 161
EP - 167
JO - Clinical Immunology
JF - Clinical Immunology
IS - 2
ER -